Latest Health News

RPMGlobal Holdings has announced a 12-month extension to its on-market share buy-back program, adding up to 11 million shares to be repurchased. This move underscores the company’s confidence in its valuation and capital management strategy.

Recce Pharmaceuticals has secured a significant patent acceptance in China for its RECCE® anti-infectives, broadening its intellectual property footprint in the world’s second-largest pharmaceutical market.

Experience Co Limited has announced a significant on-market share buy-back of up to 10% of its issued capital, signaling renewed confidence in its financial health and future prospects.

Viva Leisure has taken a strategic 33% stake in Gorilla X Labs, aiming to deepen its footprint in the sports nutrition market and enhance member offerings across its platforms.

TruScreen Group Ltd reports a dip in FY25 sales but forecasts a robust rebound in FY26 driven by resumed programs and expansion in key emerging markets. Strategic partnerships and AI-enabled technology underpin its growth ambitions.

TruScreen Group Limited reported a 19% revenue decline in FY2025 due to delayed rollouts in key emerging markets but anticipates a strong rebound with FY2026 sales forecast to exceed NZ$2.8 million.

Noble Helium has secured significant cost savings by negotiating the removal of the Marriott rig from Tanzania at no economic risk, while preparing a leaner drilling approach with the BorExpert rig.

Elders Limited has reported a robust 67% increase in underlying EBIT for the first half of FY25, driven by higher livestock prices and strategic acquisitions, while navigating challenges from dry weather impacting crop inputs.

Elders Limited reported a robust half-year performance for the period ending 31 March 2025, with profit after tax surging 190% to $33.6 million and revenue rising 5% to $1.41 billion. The company’s growth was driven by strong livestock prices, real estate acquisitions, and disciplined cost management.

Proteomics International has validated its PromarkerEndo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis, with commercial launch planned in Australia for Q3 2025. The test promises to reduce the average seven-year diagnostic delay by providing a simple risk score applicable across all disease stages.

3P Learning forecasts steady revenue for FY25 but anticipates a significant 20% uplift in underlying EBITDA and a stronger net cash position, driven by strategic product expansions.

Lucapa Diamond Company and its subsidiaries have appointed voluntary administrators as they embark on a dual-track recapitalisation and sale process to address financial distress.